X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

BAP1 (C-4) antibody

RRID:AB_626723

Antibody ID

AB_626723

Target Antigen

BAP1 (C-4) mouse, rat, human, mouse, rat, human

Proper Citation

(Santa Cruz Biotechnology Cat# sc-28383, RRID:AB_626723)

Clonality

monoclonal antibody

Comments

validation status unknown check with seller; recommendations: Immunohistochemistry; Immunocytochemistry; Western Blot; Immunofluorescence; ELISA; Immunoprecipitation; WB, IP, IF, IHC(P), ELISA

Host Organism

mouse

Vendor

Santa Cruz Biotechnology

Cat Num

sc-28383

Publications that use this research resource

Systematic Functional Annotation of Somatic Mutations in Cancer.

  • Ng PK
  • Cancer Cell
  • 2018 Mar 12

Literature context:


Abstract:

The functional impact of the vast majority of cancer somatic mutations remains unknown, representing a critical knowledge gap for implementing precision oncology. Here, we report the development of a moderate-throughput functional genomic platform consisting of efficient mutant generation, sensitive viability assays using two growth factor-dependent cell models, and functional proteomic profiling of signaling effects for select aberrations. We apply the platform to annotate >1,000 genomic aberrations, including gene amplifications, point mutations, indels, and gene fusions, potentially doubling the number of driver mutations characterized in clinically actionable genes. Further, the platform is sufficiently sensitive to identify weak drivers. Our data are accessible through a user-friendly, public data portal. Our study will facilitate biomarker discovery, prediction algorithm improvement, and drug development.

Funding information:
  • NCI NIH HHS - P30 CA016672()
  • NHLBI NIH HHS - HL-090775(United States)

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

  • Kolluri KK
  • Elife
  • 2018 Jan 18

Literature context:


Abstract:

Malignant mesothelioma (MM) is poorly responsive to systemic cytotoxic chemotherapy and invariably fatal. Here we describe a screen of 94 drugs in 15 exome-sequenced MM lines and the discovery of a subset defined by loss of function of the nuclear deubiquitinase BRCA associated protein-1 (BAP1) that demonstrate heightened sensitivity to TRAIL (tumour necrosis factor-related apoptosis-inducing ligand). This association is observed across human early passage MM cultures, mouse xenografts and human tumour explants. We demonstrate that BAP1 deubiquitinase activity and its association with ASXL1 to form the Polycomb repressive deubiquitinase complex (PR-DUB) impacts TRAIL sensitivity implicating transcriptional modulation as an underlying mechanism. Death receptor agonists are well-tolerated anti-cancer agents demonstrating limited therapeutic benefit in trials without a targeting biomarker. We identify BAP1 loss-of-function mutations, which are frequent in MM, as a potential genomic stratification tool for TRAIL sensitivity with immediate and actionable therapeutic implications.

Funding information:
  • Cancer Research UK - A17341()
  • NINDS NIH HHS - R01NS043915(United States)
  • Wellcome - WT097452MA()
  • Wellcome Trust - 106555/Z/14/Z()
  • Wellcome Trust - WT107963AIA()